MedTrace Logo

Juno Perth Clinical Trial

NCT02317042 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-06-08

Study results available
· View outcomes & findings →

Summary

This study is to evaluate the efficacy of a new therapy (Automatic Expiratory Positive Airway Pressure with intelligent Volume Assured Pressure Support (AutoEPAP iVAPS)) designed to treat respiratory insufficiency, respiratory failure and/or nocturnal hypoventilation with upper airway obstruction. The study will be performed in two phases: In a sleep unit and in the home environment. The new therapy will be compared against two existing ventilator therapies: "Spontaneous Timed (ST) mode" and "Intelligent Volume Assured Pressure Support (iVAPS)".

Conditions

  • Respiratory Insufficiency
  • Obesity Hypoventilation Syndrome
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Neuromuscular Disease
  • Upper Airway Obstruction

Interventions

DEVICE

Juno

Juno device set to ST mode with participant's current therapy settings.

DEVICE

Juno

Juno device set to AutoEPAP iVAPS mode.

DEVICE

Juno

Juno device set to Fixed EPAP iVAPS mode.

Sponsors & Collaborators

  • Sir Charles Gairdner Hospital

    collaborator OTHER

  • The University of Western Australia

    collaborator OTHER

  • ResMed

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-29
Primary Completion
2015-11-30
Completion
2015-11-29

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02317042 on ClinicalTrials.gov